ImmunoThera
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $135M
Overview
Developing next-generation vaccines and immunotherapies for infectious diseases and oncology.
Infectious DiseaseOncology
Technology Platform
Proprietary adjuvant and delivery platforms designed to enhance immunogenicity for vaccines and cancer immunotherapies.
Funding History
1Total raised:$135M
Series C$135M
Opportunities
Addressing significant unmet needs in vaccine-preventable diseases and creating more effective combinations in cancer immunotherapy.
Risk Factors
High clinical development hurdles and intense competition in both infectious disease and oncology markets.
Competitive Landscape
Competes with large vaccine manufacturers (e.g., Moderna, GSK) and numerous immuno-oncology companies developing cancer vaccines.